RhumbLine Advisers’s Elanco Animal Health ELAN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.1M | Sell |
1,264,159
-4,044
| -0.3% | -$93.5K | 0.02% | 558 |
|
|
2026
Q1 | $30.3M | Buy |
1,268,203
+24,519
| +2% | +$599K | 0.03% | 547 |
|
|
2025
Q4 | $28.1M | Sell |
1,243,684
-76,086
| -6% | -$1.66M | 0.02% | 570 |
|
|
2025
Q3 | $26.6M | Buy |
1,319,770
+865,420
| +190% | +$14.5M | 0.02% | 612 |
|
|
2025
Q2 | $6.49M | Sell |
454,350
-20,136
| -4% | -$235K | 0.01% | 1278 |
|
|
2025
Q1 | $4.98M | Sell |
474,486
-6,952
| -1% | -$78.6K | ﹤0.01% | 1359 |
|
|
2024
Q4 | $5.83M | Buy |
481,438
+2,209
| +0.5% | +$28.9K | 0.01% | 1342 |
|
|
2024
Q3 | $7.04M | Sell |
479,229
-1,840
| -0.4% | -$25.6K | 0.01% | 1239 |
|
|
2024
Q2 | $6.94M | Sell |
481,069
-15,127
| -3% | -$242K | 0.01% | 1213 |
|
|
2024
Q1 | $8.08M | Sell |
496,196
-68,574
| -12% | -$1.07M | 0.01% | 1154 |
|
|
2023
Q4 | $8.42M | Buy |
564,770
+2,560
| +0.5% | +$29K | 0.01% | 1143 |
|
|
2023
Q3 | $6.32M | Sell |
562,210
-1,406
| -0.2% | -$16.3K | 0.01% | 1220 |
|
|
2023
Q2 | $5.67M | Buy |
563,616
+82,840
| +17% | +$769K | 0.01% | 1303 |
|
|
2023
Q1 | $4.52M | Sell |
480,776
-9,375
| -2% | -$111K | 0.01% | 1388 |
|
|
2022
Q4 | $5.99M | Buy |
490,151
+23,630
| +5% | +$295K | 0.01% | 1185 |
|
|
2022
Q3 | $5.79M | Buy |
466,521
+23,563
| +5% | +$412K | 0.01% | 1143 |
|
|
2022
Q2 | $8.7M | Buy |
442,958
+68,239
| +18% | +$1.62M | 0.01% | 962 |
|
|
2022
Q1 | $9.78M | Buy |
374,719
+18,387
| +5% | +$490K | 0.01% | 960 |
|
|
2021
Q4 | $10.1M | Buy |
356,332
+10,827
| +3% | +$337K | 0.01% | 976 |
|
|
2021
Q3 | $11M | Sell |
345,505
-32,764
| -9% | -$1.1M | 0.01% | 903 |
|
|
2021
Q2 | $13.1M | Sell |
378,269
-22,706
| -6% | -$749K | 0.02% | 847 |
|
|
2021
Q1 | $11.8M | Sell |
400,975
-34,524
| -8% | -$1.06M | 0.02% | 886 |
|
|
2020
Q4 | $13.4M | Buy |
435,499
+55,059
| +14% | +$1.68M | 0.02% | 758 |
|
|
2020
Q3 | $10.6M | Sell |
380,440
-30,776
| -7% | -$780K | 0.02% | 739 |
|
|
2020
Q2 | $8.82M | Buy |
411,216
+12,074
| +3% | +$267K | 0.01% | 847 |
|
|
2020
Q1 | $8.94M | Buy |
399,142
+49,774
| +14% | +$1.36M | 0.02% | 708 |
|
|
2019
Q4 | $10.3M | Buy |
349,368
+6,238
| +2% | +$170K | 0.02% | 817 |
|
|
2019
Q3 | $9.12M | Buy |
343,130
+10,440
| +3% | +$313K | 0.02% | 819 |
|
|
2019
Q2 | $11.2M | Buy |
332,690
+37,389
| +13% | +$1.21M | 0.02% | 717 |
|
|
2019
Q1 | $9.47M | Buy |
295,301
+226,516
| +329% | +$6.97M | 0.02% | 783 |
|
|
2018
Q4 | $2.17M | Buy |
+68,785
| New | +$2.25M | ﹤0.01% | 1595 |
|
Other funds holding ELAN
RhumbLine Advisers's ELAN Position: Q2 2026 in Review
RhumbLine Advisers reduced its Elanco Animal Health (ELAN) stake by 0.32% in Q2 2026, selling an estimated $93.5K and leaving 1,264,159 shares worth $31.1M. The position accounts for 0.02% of the portfolio, ranked #558.
RhumbLine Advisers first reported a position in ELAN in Q4 2018 and has held it in 31 quarters since. 523 funds tracked by Wall St. Rank hold ELAN as of Q2 2026.
- RhumbLine Advisers held 1,264,159 shares of Elanco Animal Health worth $31.1M as of Q2 2026.
- RhumbLine Advisers sold 4,044 Elanco Animal Health shares in Q2 2026, an estimated $93.5K.
- Elanco Animal Health made up 0.02% of RhumbLine Advisers's portfolio in Q2 2026, its #558 holding.
- RhumbLine Advisers first reported a position in Elanco Animal Health in Q4 2018 and has held it in 31 quarters since.
- 523 funds tracked by Wall St. Rank held Elanco Animal Health as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.